Iguratimod inhibits protein citrullination and inflammation by downregulating NBCe2 in patients with rheumatoid arthritis

Biomed Pharmacother. 2024 May:174:116551. doi: 10.1016/j.biopha.2024.116551. Epub 2024 Apr 18.

Abstract

Background: Bicarbonate has recently been identified as a crucial factor affecting peptidylarginine deiminase (PAD) activity; however, the mechanism underlying its role in rheumatoid arthritis (RA) remains unclear. Iguratimod (IGU), a small-molecule disease-modifying anti-rheumatic drug, requires further investigation. This study aimed to explore the mechanism by which bicarbonate affects citrullination and inflammation in RA and identify new targets for IGU.

Methods: We enrolled 20 patients with RA in the study. Sodium bicarbonate cotransporter 2 (NBCe2) was detected in the peripheral blood neutrophils and peripheral blood mononuclear cells (PBMCs) of these patients. The effects of varying concentrations of IGU, methotrexate (MTX), dexamethasone (DXM), and S0859 (an NBCe2 inhibitor) on NBCe2, PAD2, PAD4, and citrullinated histone H3 (cit-H3) levels in, migration ability of, and cytokine production from neutrophils and PBMCs were examined.

Results: Our findings showed that in patients with RA, citrullinated protein production by peripheral blood neutrophils instead of PBMCs, which showed higher NBCe2 expression levels, increased with an increase in the bicarbonate concentration. In addition, tumor necrosis factor-alpha (TNF-α) promoted NBCe2 expression in neutrophils from patients with RA. Furthermore, we revealed that the inhibitory effects of IGU on neutrophil NBCe2 and cit-H3 levels, degrees of inhibition of neutrophil and PBMC migration, and suppression of interleukin 6, TNF-α, and metalloproteinase-9 secretion from neutrophil-like differentiated HL-60 cells did not substantially differ from those of MTX, DXM, and S0859 at specific doses.

Conclusions: Bicarbonate promotes protein citrullination and inflammation in RA via NBCe2, and IGU can downregulate NBCe2.

Keywords: Citrullination; Iguratimod; Methotrexate; Peptidylarginine deiminase; Sodium bicarbonate cotransporter 2; rheumatoid arthritis.

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / metabolism
  • Cell Movement / drug effects
  • Chromones* / pharmacology
  • Citrullination* / drug effects
  • Cytokines / metabolism
  • Down-Regulation* / drug effects
  • Female
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Leukocytes, Mononuclear* / drug effects
  • Leukocytes, Mononuclear* / metabolism
  • Male
  • Middle Aged
  • Neutrophils* / drug effects
  • Neutrophils* / metabolism
  • Protein-Arginine Deiminase Type 2 / metabolism
  • Protein-Arginine Deiminase Type 4 / metabolism
  • Sulfonamides* / pharmacology

Substances

  • iguratimod
  • Chromones
  • Sulfonamides
  • Antirheumatic Agents
  • Protein-Arginine Deiminase Type 2
  • Cytokines
  • Protein-Arginine Deiminase Type 4